Deep learning noise reduction in lower-dose amyloid PET scans for Alzheimer disease
Tests a deep learning image filter on simulated lower-dose amyloid PET scans in Alzheimer disease.
Key facts
- Who runs it
- Central Hospital, Nancy, France
- Where
- Vandœuvre-lès-Nancy, FranceSee the 3 sites
- Trial code
- Registry title
- Deep Learning on Amyloid Positons Emission Tomography
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 6 May 2026
- Expected to end
- 30 Jan 2027
- Type of study
- Observational
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with measurable memory or thinking problems who had a brain amyloid PET scan with [18F]flutemetamol at the study department between January 1, 2023 and July 1, 2025.
- Age
- 18 to 99 years
- Sex
- All sexes can join.
- Disease stage
- Objective cognitive impairment (measurable memory or thinking problems).
Main reasons for not taking part
- Patients who have objected to the use of their data cannot join.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients with objective cognitive impairment,
- Referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,
Who cannot take part
- Patient have objected to the use of their data
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in France
- CHRU NANCY Brabois, nuclear medicine departmentVandœuvre-lès-Nancy, FranceContact: Antoine AV VERGER, MD,PhDTaking people
- Nancy's hospitalVandœuvre-lès-Nancy, FranceContact: Antoine Verger, PhDTaking people
- Nuclear medicine department CHRU de NANCY BraboisVandœuvre-lès-Nancy, FranceContact: VERONIQUE ROCH, MScTaking people
About the trial
What the trial wants to find out
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of [18F]flutemetamol.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact of Deep Learning-Based Noise Reduction Algorithm on Visual Analysis and Centiloid Quantification in Reduced-Dose and, or Time Acquisition Amyloid PET Imaging
- Plain-language title
- Deep learning noise reduction in lower-dose amyloid PET scans for Alzheimer diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07309107, who can take part
- Record updated
- 25 June 2026